CORDIS · 259679 · FP7
IDEAL Integrated research on DEvelopmental determinants of Aging and Longevity
Coordinator: ACADEMISCH ZIEKENHUIS LEIDEN (NL)
IDEAL will obtain insight into the role of early life conditions affecting late-life health, disease and aging, and the role of epigenetic regulation therein. IDEAL will identify the determinants and targets of this epigenetic regulation utilizing a resource of unique human cohorts and animal studies that allow testing of hypotheses on the link between development and aging.Key objectives of IDEAL are1.Quantify the role of epigenetic regulation in the response to developmental conditions that affect growth & metabolism, immunity, and reproduction in animal models and its translation to human …
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
EU contribution: €12.0M awarded to the consortium. The project runs over approximately 5 years from 2011-02-01 to 2016-01-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from NL
see all →- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · H2020 · €92.5M
- GN5-2 — GN5-2101194278 · HORIZON · €80.0M
- GN4-3 — Horizon 2020: H2020-SGA-INFRA-GEANT-2018 (Topic [a] Research and Education Networking)856726 · H2020 · €77.5M
- GN4-2 — GN4-2 Research and Education Networking - GÉANT731122 · H2020 · €59.0M
- GN5-1 — GN5-1101100680 · HORIZON · €55.0M
- BIGPICTURE — Central Repository for Digital Pathology945358 · H2020 · €32.3M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the CP-IP funding scheme.
- What is the EU contribution?
- The European Commission contributes €12.0M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by ACADEMISCH ZIEKENHUIS LEIDEN (NL).
- What is the project timeline?
- The project runs from 2011-02-01 to 2016-01-31 — approximately 5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 259679.